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Most toxicologists were pleased when the National Research
Council appointed a committee in 2004 to review established
methodologies and develop a long-range vision and strategy
for toxicity testing in the future. This committee reviewed
reports from the U.S. Environmental Protection Agency (EPA)
and other sources and issued an interim report in 2006 entitled
‘‘Toxicity Testing for Assessment of Environmental Agents’’
(NCR, 2006). This report distinguished general toxicity tests
from those designed to evaluate speciﬁc health effects and
classiﬁed such tests as battery, tiered or tailored depending
on the approach. It also reviewed the use of human data,
alternative approaches and emerging technologies. Three
chapters in this report included cogent committee observations
and these sections plus the summarized information in boxes,
tables and the appendix make this soft-cover report a valuable
reference companion for the subsequent hard cover report. One
of the many observations in this report is that toxicity testing
protocols never die but unlike old soldiers who fade away,
‘‘grow like Topsy’’ (e.g., derived from the character, Topsy, in
Harriet Beecher Stowe’s Uncle Tom’s Cabin; to ‘‘grow like
Topsy’’ is to grow ‘wild, with neither plan, structure or
direction) in response to new perceived or real safety concerns.
This approach results in a cookbook/checklist of protocols
which is increasingly difﬁcult to apply efﬁciently in the testing
of new agents and is totally inadequate to deal with the
substantial backlog of untested existing substances prioritized
for consideration in evolving regulatory mandates.
The ﬁnal report from this committee, ‘‘Toxicity Testing in
the 21st Century: A Vision and a Strategy’’ was issued in 2007
(NCR, 2007a). One of the most important contributions of this
new strategy is that it attempts to integrate exciting develop-
ments such as those in toxicogenomics and other approaches
(NRC, 2007b) to increase efﬁciency and relevance of toxicity
testing to risk assessment. The advocated use of human cells or
tissues has potential to eliminate the need for interspecies
extrapolation, to increase efﬁciencies in testing and to reduce
the use of animals. An obvious criticism of this approach is that
it will not work in complex systems such as the central nervous
system where any pathway perturbation observed in animals or
human cells or systems may be many steps away from the site
of damage. And while the use of information from cells or
tissues (in vitro) to predict effects in the whole organism
(in vivo) presents challenges, it is premature to conclude that
theycannotbeaddressedintheimplementationofthevisionand
strategy in this report. Rather, what undermines signiﬁcantly
both the content and likely impact of the report is meaningful
considerationofimmediateregulatorychallengesandassociated
advances and opportunities. Greater attention by the committee
to better understand these pressures and advances might have
led to efﬁcient and pragmatic short term bridging strategies to
increase likely success in long term advancement. It would have
also reduced the potential of alienating those which it is most
trying to inﬂuence.
While it is recognized that the principal objective of the
committee exercise was development of a long-range vision
and strategy, these additional aspects would seem to be critical
to the stated objectives of the 2009 follow-up paper ‘‘Toxicity
Testing in the 21st Century: Bringing the Vision to Life’’ by
Andersen and Krewski (2009). Indeed, this document is
intended to ‘‘initiate a dialog to identify challenges in
implementing the vision and address obstacles to change.’’
Our comments, then, address two principal concerns: the ﬁrst is
that the strategy does not adequately distinguish between
effects and adverse effects in a context with which the
toxicological and risk assessment communities are currently
familiar and the second is that understanding and consideration
of the role of existing developments and barriers in regulatory
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Allbiologicaleffects aretheresultofaninteractionbetweenan
agent and a target and this interaction is deﬁned by the exposure
(dose and time).The agent isdeﬁnedbythe effects itcan produce
following single or repeated exposures and the target by its
susceptibility to these effects. All of these effects result from the
action of the agent on the target (dynamics) or from the action of
the target on the agent (kinetics) and the rate-limiting reactions
(key events) can occur in either pathway (Rozman and Doull,
2001). The goal of the strategy proposed in this report is to use
high-throughput testingtodetectearly pathwayperturbations that
disrupt normal function in the dynamic pathway. Agents such as
dioxin and asbestos where the key events occur in the kinetic
pathwaywillrequire a differentapproach.Thereportalsoequates
the initial perturbations as predictors of adversity but as shown in
Figure 2 of Andersen and Krewski (2009) adaptation can reverse
such changes if they do not exceed the homeostatic limits. Thus
theseinitialperturbationsarenotnecessarilyadverse.Mostagents
exhibit more than one effect with increasing exposure. These
effects generally have different mechanisms or modes of action
and would be expected to cause perturbations in several different
pathways. Our concern is that agents will produce multiple
perturbations of dynamic pathways and the testing strategy
proposed in this report needs a clearly deﬁned approach to
categorizetheseeffectsasbeneﬁcial,adverseorirrelevant(normal
variation) in the context of existing approaches in order to
achieve credibility as a risk assessment tool with the regulatory
community.
Inconsideringtheprerequisitesforestablishingthecredibility
of the new testing strategy in Chapter 6 of the 2007 report, the
committee concluded that validation and adversity were critical
issues. Validation is considered in chapter 5; however, adversity
is addressed only to the extent that ‘‘additional research’’ was
advocated to link effects to apical responses in animals. Part of
the difﬁculty in addressing this aspect may be a poor ﬁt with the
four elements that frequently deﬁne adversity in regulatory
guidelines (pathologic lesions, functional impairment, de-
creased susceptibility and biochemical change) which were
suggested in 1980 and are overdue for re-evaluation and
updating. A pragmatic and seemingly essential ﬁrst step in
addressing this re-evaluation of adversity would be a recom-
mendation to relate early perturbations to apical endpoints in
frameworks designed to systematically address consideration of
key events in modes of action and their subsequent implications
fordose-responseinriskassessment(seee.g.,Meek,2008).This
would be instrumental in advancing common understanding in
both the research and risk assessment communities in potential
appropriate application of data on early events in a toxicity
pathway.Increasing experience in this context could provide the
necessary basis for revisiting regulatory guidelines.
During our presentation to the NRC committee in 2005, we
also addressed the importance of linking the vision of the
committee to other on-going activities in regulatory risk
assessment, the need to address critical challenges in moving
the regulatory community towards the use of this approach and
better balance of the focus on hazard with that on exposure. In
fact, the ultimate performance indicator under progressive
chemicals legislation currently is not testing and assessment
but effective and efﬁcient management of risk. Indeed, delay
incurred by redesign of toxicity testing is inconsistent with
current regulatory objectives worldwide to be more proactive
in this area. Greater understanding and focus to more mean-
ingfully address these regulatory pressures for informed
management over the short term drawing maximally on
existing toxicological data as part of a longer term strategy to
develop more risk-based and efﬁcient testing strategies likely
has much more potential to meaningfully impact.
In particular, there has been no attempt to understand and/or
integrate pragmatic developments in several jurisdictions (in
particular in Canada and Europe) to address progressive
regulatory requirements to efﬁciently consider much larger
numbers of chemical substances. This includes tools developed
to consider priorities from amongst the 23,000 compounds
included on the Domestic Substances list under the Canadian
Environmental Protection Act (Meek and Armstrong, 2007) and
intelligent or integrated hierarchical testing strategies being
developed in Europe for implementation of the legislation for
Registration, Evaluation, and Authorization of Chemical Sub-
stances (Van Leeuwen et al., 2007). Objectives of initiatives
under these programs relevant to the content of Andersen and
Krewski(2009)includemaximallydrawinguponexistingdataon
toxicity, as a basis to increase efﬁciency. The former also
considered prioritization on the basis of much simpler and more
discerning data and tools for the signiﬁcantly potentially more
inﬂuential component of risk assessment, namely exposure
estimation. And while the predictive capacity of current com-
putational technologies such as (quantitative) structure activity
relationship analysis (including the threshold of toxicological
concern) (Renwick et al., 2003) is necessarily limited currently
owing principally to the nature of available toxicological data,
their meaningful consideration has important implications for the
design of future toxicity testing strategies including focus on
coverage of ‘‘chemical space’’ versus individual substances as
a critical criterion to increase efﬁciency and focus on in vitro
testing strategies for particular modes of action for speciﬁc
endpoints. These approaches also require limited new resources
and promote more effective and efﬁcient use of existing data as
a basis to meaningfully contribute to early risk management.
Also lacking is any meaningful strategy to address
competing science policy pressures to adopt simpliﬁed
‘‘default’’ approaches based on existing though limited toxi-
cological data, as an alternative to developing more relevant
and informative testing strategies. Relevant to this aspect are
recommendations included in a recent report also from the
NRC, entitled ‘‘Science and Decisions: Advancing Risk
Assessment’’ (NCR, 2008). It is recommended therein that
regulatory agencies such as EPA should work toward the
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implicit defaults and further, that clear, general standards for
the level of evidence needed to justify the use of alternative
assumptions in please of defaults. While transparency in
consideration and weighting of various options to estimate risk
is essential, existing bias to the use of default, regardless of its
comparatively (often limited) basis adversely impacts incentive
to develop more relevant and accurate methodology for testing
and assessment. This bias results, in large part, from the
seemingly greater onus to justify deviation from default, on the
basis of principally implicit potentially erroneous science
policy consideration that default is always protective.
It seems to us, then, that the most signiﬁcant contribution of
the report on ToxicityTesting in the 21st Century is to provide
a powerful new approach to detect and characterize biological
effects (e.g., ‘‘a new Ames test’’?). Lacking, however, and likely
to signiﬁcantly undermine its impact is the lack of consideration
of a short term strategy to transition from existing approaches in
toxicity testing and to take into account, evolving regulatory
pressures and associated pragmatic recent developments which
more efﬁciently and effectively focus effort based on existing
data (e.g., ‘‘a new edition of the Red Book’’?). The strategy also
fails to address what is likely its greatest barrier to its
implementation, namely continued bias to adoption of relatively
uninformed default approaches, based on implicit (and
potentially erroneous) science policy judgments. Without this
understanding and focus, our answer to the question posed in
the title of this paper is that the proposed strategy is more like a
new Ames test than a new edition of the ‘‘Red Book’’.
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